Valion Bio, Inc. Operating Income
Valion Bio, Inc. (VBIO) reported Operating Income of -$6.42 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-14
- Valion Bio, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$6.42M.
- Valion Bio, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$5.63M.
- Valion Bio, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$1.98M.
- Valion Bio, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$2.48M.
- Valion Bio, Inc. operating income (loss) for fiscal 2025 was -$7.90M.
- Valion Bio, Inc. operating income (loss) for fiscal 2024 was -$4.48M.
- Valion Bio, Inc. operating income (loss) for fiscal 2023 was -$8.24M.
- Valion Bio, Inc. operating income (loss) for fiscal 2022 was -$10.10M.
| Period end | Operating Income (Loss) 1 month | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 6 month as first filed | Operating Income (Loss) 9 month | Operating Income (Loss) 9 month as first filed | Operating Income (Loss) 12 month | Operating Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$6.42M 10-Q · filed 2026-08-14 | -$12.06M 10-Q · filed 2026-08-14 | -$14.03M derived: sum of 3 quarters · filed 2026-08-14 | -$16.52M derived: sum of 4 quarters · filed 2026-08-14 | |||||
| 2026-03-31 | -$5.63M 10-Q · filed 2026-05-14 | -$7.61M derived: sum of 2 quarters · filed 2026-05-14 | -$10.09M derived: sum of 3 quarters · filed 2026-05-14 | -$11.77M derived: sum of 4 quarters · filed 2026-08-14 | |||||
| 2025-12-31 | -$1.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$4.46M derived: sum of 2 quarters · filed 2026-03-30 | -$6.14M derived: sum of 3 quarters · filed 2026-08-14 | -$7.90M 10-K · filed 2026-03-30 | |||||
| 2025-09-30 | -$2.48M 10-Q · filed 2025-11-14 | -$4.16M derived: sum of 2 quarters · filed 2026-08-14 | -$5.92M 10-Q · filed 2025-11-14 | -$5.84M derived: sum of 4 quarters · filed 2026-08-14 | |||||
| 2025-06-30 | -$1.68M 10-Q · filed 2026-08-14 | -$1.93M 10-Q · filed 2025-08-14 | -$3.06M 10-Q · filed 2026-08-14 | -$3.44M 10-Q · filed 2025-08-14 | -$3.35M derived: sum of 3 quarters · filed 2026-08-14 | -$4.78M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-03-31 | -$1.38M 10-Q · filed 2026-05-14 | -$1.51M 10-Q · filed 2025-05-15 | -$1.68M derived: sum of 2 quarters · filed 2026-05-14 | -$3.11M derived: sum of 3 quarters · filed 2026-05-14 | -$4.37M derived: sum of 4 quarters · filed 2026-05-14 | ||||
| 2024-12-31 | -$298.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$1.73M derived: sum of 2 quarters · filed 2026-03-30 | -$3.00M derived: sum of 3 quarters · filed 2026-03-30 | -$4.48M 10-K · filed 2026-03-30 | -$5.66M 10-K · filed 2025-03-21 | ||||
| 2024-09-30 | -$1.43M 10-Q · filed 2025-11-14 | -$2.70M derived: sum of 2 quarters · filed 2025-11-14 | -$4.18M 10-Q · filed 2025-11-14 | -$4.12M 10-Q · filed 2024-11-14 | -$6.42M derived: sum of 4 quarters · filed 2025-11-14 | ||||
| 2024-06-30 | -$1.27M 10-Q · filed 2025-08-14 | -$1.21M 10-Q · filed 2024-08-14 | -$2.75M 10-Q · filed 2025-08-14 | -$2.69M 10-Q · filed 2024-08-14 | -$4.99M derived: sum of 3 quarters · filed 2025-08-14 | -$6.75M derived: sum of 4 quarters · filed 2025-08-14 | |||
| 2024-03-31 | -$1.48M 10-Q · filed 2025-05-15 | -$3.73M derived: sum of 2 quarters · filed 2025-05-15 | -$5.49M derived: sum of 3 quarters · filed 2025-05-15 | -$7.61M derived: sum of 4 quarters · filed 2025-05-15 | |||||
| 2023-12-31 | -$2.24M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | -$4.00M derived: sum of 2 quarters · filed 2025-03-21 | -$6.13M derived: sum of 3 quarters · filed 2025-03-21 | -$8.24M 10-K · filed 2025-03-21 | |||||
| 2023-09-30 | -$1.76M 10-Q · filed 2024-11-14 | -$3.88M derived: sum of 2 quarters · filed 2024-11-14 | -$6.00M 10-Q · filed 2024-11-14 | -$8.26M derived: sum of 4 quarters · filed 2024-11-14 | |||||
| 2023-06-30 | -$2.13M 10-Q · filed 2024-08-14 | -$4.24M 10-Q · filed 2024-08-14 | -$6.50M derived: sum of 3 quarters · filed 2024-08-14 | -$9.08M derived: sum of 4 quarters · filed 2024-08-14 | |||||
| 2023-03-31 | -$2.12M 10-Q · filed 2024-05-15 | -$4.37M derived: sum of 2 quarters · filed 2024-05-15 | -$6.96M derived: sum of 3 quarters · filed 2024-05-15 | -$9.97M derived: sum of 4 quarters · filed 2024-05-15 | |||||
| 2022-12-31 | -$2.26M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | -$4.84M derived: sum of 2 quarters · filed 2024-03-25 | -$7.86M derived: sum of 3 quarters · filed 2024-03-25 | -$10.10M 10-K · filed 2024-03-25 | |||||
| 2022-09-30 | -$2.58M 10-Q · filed 2023-11-14 | -$5.60M derived: sum of 2 quarters · filed 2023-11-14 | -$7.84M 10-Q · filed 2023-11-14 | -$10.13M derived: sum of 4 quarters · filed 2023-11-14 | |||||
| 2022-06-30 | -$3.02M 10-Q · filed 2023-08-14 | -$5.26M 10-Q · filed 2023-08-14 | -$7.55M derived: sum of 3 quarters · filed 2023-08-14 | -$8.78M derived: sum of 4 quarters · filed 2023-08-14 | |||||
| 2022-03-31 | -$2.24M 10-Q · filed 2023-05-15 | -$4.53M derived: sum of 2 quarters · filed 2023-05-15 | -$5.76M derived: sum of 3 quarters · filed 2023-05-15 | -$6.82M derived: sum of 4 quarters · filed 2023-05-15 | |||||
| 2022-01-31 | -$2.24M 10-Q · filed 2022-05-16 | ||||||||
| 2021-12-31 | -$2.29M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$3.52M derived: sum of 2 quarters · filed 2023-03-31 | -$4.58M derived: sum of 3 quarters · filed 2023-03-31 | -$5.63M 10-K · filed 2023-03-31 | |||||
| 2021-09-30 | -$1.23M 10-Q · filed 2022-11-14 | -$2.28M derived: sum of 2 quarters · filed 2022-11-14 | -$3.34M 10-Q · filed 2022-11-14 | ||||||
| 2021-06-30 | -$1.05M 10-Q · filed 2022-08-15 | -$2.11M 10-Q · filed 2022-08-15 | |||||||
| 2021-03-31 | -$1.06M 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |